NASDAQ:CLLS
Cellectis S.A. Stock Insider Trading
There is currently no insider trading information for this ticker.
However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
